Senzar Asset Management LLC lifted its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 17.1% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 4,087,264 shares of the biopharmaceutical company’s stock after buying an additional 597,400 shares during the period. Halozyme Therapeutics makes up approximately 12.9% of Senzar Asset Management LLC’s holdings, making the stock its largest position. Senzar Asset Management LLC owned approximately 3.18% of Halozyme Therapeutics worth $52,399,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds have also made changes to their positions in the company. Creative Planning boosted its stake in shares of Halozyme Therapeutics by 1.2% during the second quarter. Creative Planning now owns 114,667 shares of the biopharmaceutical company’s stock worth $1,470,000 after buying an additional 1,383 shares during the period. American International Group Inc. lifted its position in Halozyme Therapeutics by 7.0% in the first quarter. American International Group Inc. now owns 67,109 shares of the biopharmaceutical company’s stock valued at $870,000 after purchasing an additional 4,407 shares during the period. Chicago Equity Partners LLC lifted its position in Halozyme Therapeutics by 85.5% in the second quarter. Chicago Equity Partners LLC now owns 315,440 shares of the biopharmaceutical company’s stock valued at $4,044,000 after purchasing an additional 145,410 shares during the period. BlackRock Inc. lifted its position in Halozyme Therapeutics by 7,292.8% in the first quarter. BlackRock Inc. now owns 11,062,842 shares of the biopharmaceutical company’s stock valued at $143,374,000 after purchasing an additional 10,913,199 shares during the period. Finally, JPMorgan Chase & Co. lifted its position in Halozyme Therapeutics by 6.1% in the first quarter. JPMorgan Chase & Co. now owns 2,915,415 shares of the biopharmaceutical company’s stock valued at $37,784,000 after purchasing an additional 168,349 shares during the period. Institutional investors and hedge funds own 85.06% of the company’s stock.
Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) traded up 1.08% during midday trading on Friday, reaching $16.78. 1,178,253 shares of the company were exchanged. The stock’s market capitalization is $2.25 billion. Halozyme Therapeutics, Inc. has a 52-week low of $8.18 and a 52-week high of $17.55. The company’s 50-day moving average price is $13.01 and its 200 day moving average price is $13.28.
Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.02. The firm had revenue of $33.80 million for the quarter, compared to analyst estimates of $31.76 million. The company’s revenue for the quarter was up 1.2% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.21) earnings per share. On average, equities analysts predict that Halozyme Therapeutics, Inc. will post ($0.22) earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This news story was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this news story on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The legal version of this news story can be accessed at https://ledgergazette.com/2017/09/24/senzar-asset-management-llc-acquires-597400-shares-of-halozyme-therapeutics-inc-halo.html.
A number of equities research analysts recently commented on the stock. Piper Jaffray Companies set a $20.00 price objective on shares of Halozyme Therapeutics and gave the company a “buy” rating in a research report on Thursday, August 10th. BMO Capital Markets raised their price objective on shares of Halozyme Therapeutics from $14.00 to $15.00 and gave the company a “market perform” rating in a research report on Friday, September 15th. BidaskClub downgraded shares of Halozyme Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, August 18th. Jefferies Group LLC restated an “underperform” rating and issued a $7.00 price objective (up previously from $6.75) on shares of Halozyme Therapeutics in a research report on Thursday, August 10th. Finally, Zacks Investment Research upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price objective for the company in a research report on Friday, August 11th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $16.00.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.
Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.